Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that new data for duvelisib (IPI-145), an oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, will be presented at the American Society of Hematology (ASH) 2014 Annual Meeting, which is being held December 6-9 in San Francisco, CA.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
